BVNKF:OTCMKTS
Bavarian Nordic A/S
$36.06
0.00%
(0.00) 1D
Oct 8, 3:46:25 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNKF...
Mkt. cap
2.82B
Avg. vol.
14.00
Volume
0.00
52-wk high
$37.22
52-wk low
$27.69
Beta
1.46
Shares outstanding
79.26M
No. of employees
2K
Mkt. cap
2.82B
Avg. vol.
14.00
Volume
0.00
52-wk high
$37.22
52-wk low
$27.69
Beta
1.46
Shares outstanding
79.26M
No. of employees
2K
News stories
From web sources and news partners
ChartMill
·
46 minutes ago
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Finbold
·
1 hour ago
This Grok portfolio just destroyed the S&P 500
Investing.com
·
1 hour ago
Dow Jones, Nasdaq, S&P 500 preview: Markets brace for CPI, Q3 earnings kick-off
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com